These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1069 related items for PubMed ID: 9725263

  • 1. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR, Majewski D, Ozker K, Hanson G.
    J Immunol; 1998 Sep 01; 161(5):2610-9. PubMed ID: 9725263
    [Abstract] [Full Text] [Related]

  • 2. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Sep 01; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M, Wettstein PJ, Korngold R.
    Transplantation; 1994 Apr 15; 57(7):1095-102. PubMed ID: 7909395
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.
    Biol Blood Marrow Transplant; 2003 Dec 15; 9(12):742-52. PubMed ID: 14677113
    [Abstract] [Full Text] [Related]

  • 8. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH, Breglio J, Nagel G, Eckhaus MA, Gress RE.
    J Immunol; 1996 Dec 01; 157(11):4811-21. PubMed ID: 8943383
    [Abstract] [Full Text] [Related]

  • 9. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR, Taylor PA, Vallera DA.
    J Immunol; 1994 Apr 01; 152(7):3665-74. PubMed ID: 8144942
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
    Blazar BR, Taylor PA, Fitzsimmons WE, Vallera DA.
    J Immunol; 1994 Aug 15; 153(4):1836-46. PubMed ID: 7519216
    [Abstract] [Full Text] [Related]

  • 13. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
    Blazar BR, Jenkins MK, Taylor PA, White J, Panoskaltsis-Mortari A, Korngold R, Vallera DA.
    J Immunol; 1997 Dec 15; 159(12):5821-33. PubMed ID: 9550378
    [Abstract] [Full Text] [Related]

  • 14. Facilitation of parental-strain marrow engraftment by T cells of neonatally-tolerant mice.
    Davenport C, George T, Devora GA, Morris MA, Gordon BE, Kumar V, Bennett M.
    Biol Blood Marrow Transplant; 1997 Dec 15; 3(6):294-303. PubMed ID: 9502296
    [Abstract] [Full Text] [Related]

  • 15. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC, Friedman TM, Murphy GF, Korngold R.
    Biol Blood Marrow Transplant; 2004 Feb 15; 10(2):91-105. PubMed ID: 14750075
    [Abstract] [Full Text] [Related]

  • 16. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
    Blazar BR, Sharpe AH, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Korngold R, Vallera DA.
    J Immunol; 1996 Oct 15; 157(8):3250-9. PubMed ID: 8871619
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.
    Krenger W, Snyder KM, Byon JC, Falzarano G, Ferrara JL.
    J Immunol; 1995 Jul 15; 155(2):585-93. PubMed ID: 7608537
    [Abstract] [Full Text] [Related]

  • 19. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
    Johnson BD, McCabe C, Hanke CA, Truitt RL.
    J Immunol; 1995 May 15; 154(10):5542-54. PubMed ID: 7730653
    [Abstract] [Full Text] [Related]

  • 20. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells.
    Rus V, Svetic A, Nguyen P, Gause WC, Via CS.
    J Immunol; 1995 Sep 01; 155(5):2396-406. PubMed ID: 7650373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.